Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium. It contains the same active moiety (esomeprazole) in a different salt form as found in the leading PPI brand Nexium^® (esomeprazole magnesium) and presents a potentially more affordable treatment option for GERD in adult patients.

Available in a 49.3 mg strength, each esomeprazole strontium capsule provides the equivalent of 40 mg of esomeprazole - the same amount of esomeprazole that is present in the 40 mg Nexium^® capsule. Esomeprazole strontium capsules will be sold in 30-count bottles and are the authorized generic equivalent for their branded counterpart by the same name (Esomeprazole strontium delayed-release capsules 49.3 mg), which Amneal launched in December 2013.

Amneal Co-CEO & Chairman Chirag Patel explains, "Introducing generic esomeprazole strontium offers a new, cost-effective treatment option for adult GERD sufferers. It's another example of how Amneal's innovative growth strategy has helped to bring economical generic medications to market and benefit all stakeholders in the healthcare equation—patients, prescribers, pharmacists and payers."

Esomeprazole strontium will be sold through wholesalers and distributors as well as directly to the trade. The product begins shipping today.

SOURCE Amneal Pharmaceuticals LLC